Showing 5171-5180 of 8889 results for "".
- South Beach Symposium Poised for 18th Miami Conferencehttps://practicaldermatology.com/news/south-beach-symposium-poised-for-18th-miami-conference/2460253/The 18th Annual South Beach Symposium takes place in Miami Beach next month. Organizers say the annual conference boasts an extensive agenda, with in-depth pre-conference offerings, and sessions topics covering the latest and most well-supported knowledge in clinical and aesthetic dermatology. Ro
- Revian Awarded Patent for Biostimulatory Light Combinationshttps://practicaldermatology.com/news/revian-awarded-patent-for-biostimulatory-light-technology/2460249/Revian Inc. has received from the United States Patent and Trademark Office (USPTO) U.S. Patent No. 10,265,258—the seminal patent on the use of proprietary color combinations of light to regenerate living tissue in the body. The claims in this issued patent cover the u
- Amorepacific Shows Off Face Mask 3D Printing System and Flexible LED Beauty Device at CES 2020https://practicaldermatology.com/news/amorepacific-shows-off-face-mask-3d-printing-system-and-flexible-led-beauty-device-at-ces-2020/2460246/Amorepacific is presenting its 3D face mask printing system (IOPE Tailored 3D Mask) and flexible LED beauty device (MakeON Flexible LED Patch) at the Consumer Electronics Show 2020 (CES 2020) in Las Vegas. Created in collaboration with the 3D printing system developer Lincsolu
- The HydraFacial Company Takes on Scalp Healthhttps://practicaldermatology.com/news/the-hydrafacial-company-takes-on-scalp-health/2460245/The HydraFacial Company is launching
- P&G to Unveil Improved Opte Precision Skincare System at CES 2020https://practicaldermatology.com/news/pg-to-unveil-improved-opte-precision-skincare-system-at-ces-2020/2460243/P&G Ventures, the startup studio within Procter & Gamble, is slated to showcase the Opte Precision Skincare System, the first personalized handheld inkjet printer to instantly make the appearance of skin's hyperpigmentation disappear and fade spots over time, at CES 2020. CE
- Study of Victoria's Secret Models Highlights Changing and Unattainable Beauty Standardshttps://practicaldermatology.com/news/study-of-victorias-secret-models-highlights-changing-and-unattainable-beauty-standards/2460242/While the average American woman's waist circumference and dress size has increased over the past 20 years, Victoria's Secret fashion models have become more slender, with a decrease in bust, waist, hips and dress size, though their waist to hip ratio (WHR) has remained constant, accordin
- DermTech’s Pigmented Lesion Assay Receives Medicare Coveragehttps://practicaldermatology.com/news/dermtechs-pigmented-lesion-assay-receives-medicare-coverage/2460241/The Medicare Administrative Contractor Palmetto GBA MolDx issued a final local coverage determination for DermTech, Inc.'s Pigmented Lesion Assay (PLA). The PLA test is used to help rule out primary cutaneous melanoma and guide biopsy decisions of melanocytic skin lesions with one or more cli
- Avita Medical Receives U.S. FDA Investigational Device Exemption Approval of Clinical Feasibility Study to Evaluate RECELL System in Vitiligohttps://practicaldermatology.com/news/avita-medical-receives-us-fda-investigational-device-exemption-approval-of-clinical-feasibility-study-to-evaluate-recell-system-in-vitiligo/2460240/The U.S. Food and Drug Administration (FDA) approved AVITA Medical’s Investigational Device Exemption (IDE) application to conduct a feasibility study evaluating the safety and effectiveness of the RECELL Autologous Cell Harvesting Device (RECELL System) for repigmentation of depigmen
- New Anti-Acne Launches from Ceravehttps://practicaldermatology.com/news/new-launches-from-cerave/2460236/CeraVe is rolling out
- Castle Creek Completes Acquisition of Fibrocell Sciencehttps://practicaldermatology.com/news/castle-creek-completes-acquisition-of-fibrocell-science/2460235/Castle Creek Pharmaceutical Holdings, Inc. completed the acquisition of Fibrocell Science, Inc. Both companies have advanced investigational therapies for the treatment of epidermolysis bullosa (EB) into late-stage clinical research. Prior to the acquisition, Fibrocell initiated a pivot